Literature DB >> 27629130

Alternative tumor markers in the diagnosis of ovarian cancer.

Burcu Kısa Karakaya, Eralp Başer1, Berk Bildacı, Esra Çabuk Cömert, Nilufer Bayraktar, Polat Dursun, Esra Kuşçu, Ali Ayhan.   

Abstract

OBJECTIVES: The aim of the study was to assess the usefulness of various tumor markers (CA125, HE4, bcl2) measured in serum, urine and saliva in the differential diagnosis of adnexal masses.
MATERIAL AND METHODS: Our study was conducted at the Başkent University Medical School, Department of Obstetrics and Gynecology, Ankara, Turkey, between November 2010 and March 2011. Fifty patients with a suspicion of malignant adnexal mass and 30 controls were included in the study. Serum and urine CA-125, HE4, and bcl2 levels were evaluated for their role in the diagnosis of epithelial ovarian cancer (EOC).
RESULTS: Serum CA-125 and HE4 levels, and urine HE4 levels were significantly higher in malignant cases as compared to controls (p < 0.05). Mean levels of bcl2 in saliva and urine were similar in malignant cases and controls (p > 0.05).
CONCLUSIONS: We demonstrated that serum CA125, serum HE4 and urine HE4 levels were elevated in patients with ovarian cancer. These findings should be assessed in future studies with larger sample sizes in order to reach more definite conclusions.

Entities:  

Keywords:  CA125; HE4; adnexal mass; bcl2; ovarian cancer; tumor marker

Mesh:

Substances:

Year:  2016        PMID: 27629130     DOI: 10.5603/GP.2016.0045

Source DB:  PubMed          Journal:  Ginekol Pol        ISSN: 0017-0011            Impact factor:   1.232


  2 in total

1.  Circular RNA as a biomarker for cancer: A systematic meta-analysis.

Authors:  Yulong Li; Xiaoli Zeng; Jianxun He; Yuan Gui; Song Zhao; Hua Chen; Qi Sun; Nan Jia; Hui Yuan
Journal:  Oncol Lett       Date:  2018-07-11       Impact factor: 2.967

2.  Urine CA125 and HE4 for the Triage of Symptomatic Women with Suspected Endometrial Cancer.

Authors:  Kelechi Njoku; Chloe E Barr; Caroline J J Sutton; Emma J Crosbie
Journal:  Cancers (Basel)       Date:  2022-07-06       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.